MEDICINOVA INC. - COMMON STOCK

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal

21 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in Maxim Group LLC Fireside Chat

14 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

07 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Reports First Quarter 2021 Financial Results and Business Update

13 May 2021 16:30:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe

05 May 2021 20:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Gene Therapy Milestone Payments

22 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the B. Riley Neuroscience Conference

19 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the UBS Global Healthcare Virtual Conference

15 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

09 Mar 2021 16:00:00 By Nasdaq GlobeNewswire

MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

08 Mar 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19

03 Mar 2021 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Closing of US$20 Million Private Placement Transaction

31 Jan 2021 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan

18 Jan 2021 18:00:00 By Nasdaq GlobeNewswire

MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners

11 Jan 2021 21:30:00 By Nasdaq GlobeNewswire